6 completed, 5 recruiting, 3 terminated, 2 active not recruiting. 17 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 17 | Completed 6, Recruiting 5, Terminated 3, Active not recruiting 2, Withdrawn 1 |
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
Follow Uremia: new trials by email Literature Review of Uremia trials Research Report on Uremia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Self-Controlled Study on the Treatment of Restless Legs Syndrome in Uremia With Dipyridamole Dipyridamole 50mg tid - Restless Leg Syndrome Due to Uraemia | Phase 2 / Phase 3 | Recruiting | Yunfeng Xia | 80 | 2025-09-20 | 2026-04-22 |
| Efficacy of INM004 in Children With STEC-HUS INM004, Placebo - Hemolytic-Uremic Syndrome | Phase 3 | Recruiting | Inmunova S.A. | 220 | 2024-10-05 | 2026-01-15 |
| Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS Iptcaopan 200 mg - Atypical Hemolytic Uremic Syndrome | Phase 3 | Recruiting | Novartis Pharmaceuticals | 65 | 2024-05-08 | 2026-06-04 |
| Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Iptacopan - Atypical Hemolytic Uremic Syndrome | Phase 3 | Recruiting | Novartis Pharmaceuticals | 50 | 2024-02-28 | 2026-04-29 |
| Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome Soliris®, Renin angiotensin system blockers - Hypertensive Emergency-associated Hemolytic Uremic Syndrome | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 66 | 2023-11-09 | 2024-01-05 |
| Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy Iptacopan - Atypical Hemolytic Uremic Syndrome | Phase 3 | Completed | Novartis Pharmaceuticals | 34 | 2022-01-17 | 2026-08-07 |
| A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Crovalimab - Atypical Hemolytic Uremic Syndrome | Phase 3 | Active not recruiting | Hoffmann-La Roche | 41 | 2021-11-17 | 2026-10-01 |
| A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Crovalimab - Atypical Hemolytic Uremic Syndrome | Phase 3 | Active not recruiting | Hoffmann-La Roche | 83 | 2021-10-22 | 2026-07-21 |
| Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring (EspacECU) Spacing of Eculizumab infusions - Hemolytic-Uremic Syndrome, Atypical | Phase 3 | Completed | University Hospital, Tours | 40 | 2021-10-20 | 2025-03-25 |
| Phase 2/3 Study to Evaluate PK, Safety & Efficacy of INM004 in STEC Positive Pediatric Patients for Prevention of HUS INM004, Placebo - Bloody Diarrhea, STEC, Unspecified | Phase 2 / Phase 3 | Terminated | Inmunova S.A. | 11 | 2019-07-17 | 2023-07-19 |
| Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome OMS721 (narsoplimab) - Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome | Phase 3 | Terminated | Omeros Corporation | 6 | 2018-05-02 | 2025-12-10 |
| Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) Ravulizumab - Atypical Hemolytic Uremic Syndrome (aHUS) | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 34 | 2017-08-31 | 2024-03-15 |
| Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Ravulizumab - Atypical Hemolytic Uremic Syndrome (aHUS) | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 58 | 2017-01-11 | 2024-02-20 |
| Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU Eculizumab, Placebo - Hemolytic Uremic Syndrome of Childhood | Phase 3 | Completed | University Hospital, Toulouse | 100 | 2015-06-01 | 2026-05-04 |
| The Plasma Large-Volume Exchange RCT Plasma Exchange - Purpura, Thrombotic Thrombocytopenic, Hemolytic Uremic Syndrome | Phase 3 | Withdrawn | London Health Sciences Centre | 2012-04-01 | 2013-04-17 | |
| Effects of Convective Therapies in Dialysis Patients online pre-dilution hemofiltration, online pre-dilution hemodiafiltration - Uremia | Phase 3 | Completed | A. Manzoni Hospital | 146 | 2003-11-01 | 2012-04-24 |
| Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome SYNSORB Pk, Placebo - Hemolytic Uremic Syndrome | Phase 3 | Terminated | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 145 | 1997-07-27 | 2017-06-01 |
Atypical Hemolytic Uremic Syndrome (10) · Hemolytic-Uremic Syndrome (6) · Thrombotic Microangiopathies (5) · Acute Kidney Injury (1) · Bacterial Infections (1) · Communicable Diseases (1) · Escherichia coli Infections (1) · Glomerulonephritis, Membranoproliferative (1) · Hypertensive Crisis (1) · Immune System Diseases (1) · Kidney Diseases (1) · Kidney Failure, Chronic (1) · Purpura, Thrombotic Thrombocytopenic (1) · Rare Diseases (1)
Female Urogenital Diseases (17) · Female Urogenital Diseases and Pregnancy Complications (17) · Male Urogenital Diseases (17) · Urologic Diseases (17) · Kidney Diseases (16) · Urogenital Diseases (16) · Anemia (15) · Anemia, Hemolytic (15) · Blood Platelet Disorders (15) · Cytopenia (15) · Hematologic Diseases (15) · Hemic and Lymphatic Diseases (15) · Thrombocytopenia (15) · Thrombotic Microangiopathies (10)
Exercise (2) · eculizumab (2) · iptacopan (2) · ravulizumab (2) · Dipyridamole (1) · Glucose (1) · Plasma Exchange (1) · SYNSORB Pk (1) · Solutions (1) · narsoplimab (1)
Novartis Pharmaceuticals (3) · Alexion Pharmaceuticals, Inc. (2) · Hoffmann-La Roche (2) · Inmunova S.A. (2) · A. Manzoni Hospital (1) · Assistance Publique - Hôpitaux de Paris (1) · London Health Sciences Centre (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Omeros Corporation (1) · University Hospital, Toulouse (1) · University Hospital, Tours (1) · Yunfeng Xia (1)
France (8) · United States (7) · China (6) · Italy (6) · Japan (6) · Belgium (5) · Canada (5) · Germany (5) · Spain (5) · Brazil (4) · India (4) · United Kingdom (4) · Poland (3) · South Korea (3) · Taiwan (3)
Arnaud Garnier, MD (1) · Francesco Locatelli, Professor (1) · Howard Trachtman (1) · Karine Brochard (1) · Santiago Sanguineti, Ph.D (1)
PMID 33783815, PMID 34219224, PMID 40277027, PMID 12966125, PMID 20813866, PMID 24557989, PMID 32299680, PMID 33048203, PMID 33407224, PMID 33693990, PMID 33774745, PMID 34169200, PMID 35123930, PMID 36329366, PMID 37303085, PMID 39105067, PMID 39468592
2016 (2), 2023 (2), 2014 (1), R01DK052147 (1)